Oncology

Endometrial Cancer

Expert Roundtables Podcast: The Use of Biomarkers in the Management of Endometrial Cancer

expert roundtables by David Scott Miller, MD, FACOG, FACS; Alexander B. Olawaiye, MD, FRCOG, FACOG, FACS; Pamela T. Soliman, MD, MPH

Overview

When combined with histological characteristics, molecular biomarkers support a personalized treatment approach for endometrial cancer. Selecting treatments based on a patient’s biomarkers may help to not only maximize treatment benefits but also prevent treatment-related toxicities in patients whose endometrial cancer is unlikely to respond to the therapies. Our featured experts explore this topic in this Expert Roundtables discussion.

References

Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. 2020;26(15):3928-3935. doi:10.1158/1078-0432.CCR-20-0953

Jamieson A, Huvila J, Leung S, et al. Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer. Gynecol Oncol. 2023;170:282-289. doi:10.1016/j.ygyno.2023.01.025

Karpel HC, Slomovitz B, Coleman RL, Pothuri B. Treatment options for molecular subtypes of endometrial cancer in 2023. Curr Opin Obstet Gynecol. 2023;35(3):270-278. doi:10.1097/GCO.0000000000000855

Swift BE, Gien LT. Incorporating molecular diagnostics into treatment paradigms for endometrial cancer. Curr Treat Options Oncol. 2022;23(8):1121-1134. doi:10.1007/s11864-022-00993-x

Walsh CS, Hacker KE, Secord AA, DeLair DF, McCourt C, Urban R. Molecular testing for endometrial cancer: an SGO clinical practice statement. Gynecol Oncol. 2023;168:48-55. doi:10.1016/j.ygyno.2022.10.024

Wong RW, Cheung ANY. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues. Pathology. 2024;56(2):214-227. doi:10.1016/j.pathol.2023.10.013

Profile

David Scott Miller, MD, FACOG, FACS

Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, TX

Profile

Alexander B. Olawaiye, MD, FRCOG, FACOG, FACS

Professor and Vice Chair for Diversity, Equity and Inclusion
Department of Obstetrics, Gynecology and Reproductive Sciences
University of Pittsburgh School of Medicine
Director, Gynecologic Cancer Research
UPMC Magee-Womens Hospital
University of Pittsburgh Medical Center
Pittsburgh, PA

Profile

Pamela T. Soliman, MD, MPH

Professor and Chair ad interim
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX